Exogenous Sex Hormones and Thrombophilia

Obstetrics and Gynecology Clinics of North America

Volumn 33, Issue 3, 2006, Pages 467-479

  Walker, Isobel D ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CONJUGATED ESTROGEN; CONTRACEPTIVE AGENT; DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; ETYNODIOL DIACETATE; GESTAGEN; GESTODENE; LEVONORGESTREL; LIPID; LYNESTRENOL; MESTRANOL; NORETHISTERONE; NORETYNODREL; NORGESTIMATE; NORGESTREL; NORGESTRIENONE; ORAL CONTRACEPTIVE AGENT; PROTEIN S; PROTHROMBIN; SEX HORMONE; UNINDEXED DRUG;

ARTERY THROMBOSIS; CEREBROVASCULAR ACCIDENT; ESTROGEN THERAPY; FEMALE; HEART INFARCTION; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; OVARY HYPERSTIMULATION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOPHILIA; VEIN THROMBOSIS;

ARTERIES; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; REPRODUCTIVE TECHNIQUES, ASSISTED; RISK FACTORS; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOSIS;

EID: 33748304390     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2006.05.008     Document Type: Review

References (113)

1. Rosendaal F.R., Helmerhorst F.M., and Vandenbroucke J.P. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22 2 (2002) 201-210
2. Jordan W.M. Pulmonary embolism. Lancet 2 (1961) 1146-1147
3. Boyce E.J., Fawcett J.W., and Noall E.W. Coronary thrombosis and Conovide. Lancet 1 (1963) 111
4. Scarabin P.Y., Plu-Bureau G., Zitoun D., et al. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity. Thromb Haemost 74 3 (1995) 928-932
5. Quehenberger P., Loner U., Kapiotis S., et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 76 5 (1996) 729-734
6. Meade T.W., Haines A.P., North W.R., et al. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet 2 8045 (1977) 948-951
7. Henkens C.M.A., Bom V.J.J., Seinen A.J., et al. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 73 3 (1995) 402-404
8. Koh K.K., Horne III M.K., and Cannon III R.O. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost 82 2 (1999) 626-633
9. Olivieri O., Friso S., Manzato F., et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 91 2 (1995) 465-470
10. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI). Study Circ 100 7 (1999) 717-722
11. Cushman M., Meilahn E.N., Psaty B.M., et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 19 4 (1999) 893-899
12. Tans G., Curvers J., Middeldorp S., et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 84 1 (2000) 15-21
13. Mackie I.J., Piegsa K., Furs S.A., et al. Protein S levels are lower in women receiving desogestrel-containing combined oral contraceptives (COCs) than in women receiving levonorgestrel-containing COCs at steady state and on cross-over. Br J Haematol 113 4 (2001) 898-904
14. Middeldorp S., Meijers J.C., van den Ende A.E., et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 84 1 (2000) 4-8
15. Meijers J.C., Middeldorp S., Tekelenburg W., et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 84 1 (2000) 9-14
16. Rosing J., Tans G., Nicolaes G.A.F., et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 97 1 (1997) 233-238
17. Caine Y.G., Bauer K.A., Barzegar S., et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 68 4 (1992) 392-395
18. Kroon U.B., Silfverstolpe G., and Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 71 4 (1994) 420-423
19. Scarabin P.Y., Alhenc-Gelas M., Plu-Bureau G., et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 17 11 (1997) 3071-3078
20. Lowe G.D.O., Rumley A., Woodward M., et al. Activated protein C resistance and the FV:R506Q mutation in a random population sample. Thromb Haemost 81 6 (1999) 918-924
21. Nabulsi A.A., Folsom A.R., White A., et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 328 15 (1993) 1069-1075
22. The Writing Group for the PEPI Trial. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The Post-menopausal Estrogen/progestin Interventions (PEPI) Trial. JAMA 273 (1995) 199-208
23. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework. BMJ 312 7029 (1996) 473-478
24. Lowe G.D., Upton M.N., Rumley A., et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein-a cross-sectional population survey. Thromb Haemost 86 2 (2001) 550-556
25. Lindoff C., Peterson F., Lecander I., et al. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease. Maturitas 24 1-2 (1996) 43-50
26. Records Unit and Research Advisory Service of the Royal College of General Practitioners. Oral contraception and thromboembolic disease. J R Coll Gen Pract 13 (1967) 267-279
27. Vessey M., Mant D., Smith A., et al. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed) 292 6519 (1986) 526
28. Porter J.B., Hunter J.R., Danielson D.A., et al. Oral contraceptives and nonfatal vascular disease-recent experience. Obstet Gynecol 59 3 (1982) 299-302
29. Sartwell P.E., Masi A.T., Arthes F.G., et al. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 90 5 (1969) 365-380
30. Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall bladder disease and breast tumours. Lancet 1 (1973) 1399-1404
31. Vessey M.P., and Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ 1 (1968) 199-205
32. Vessey M.P., and Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. BMJ 2 (1969) 651-657
33. Royal College of General Practitioners' Oral contraception Study. Oral contraceptives; venous thrombosis and varicose veins. J R Coll Gen Pract 28 (1978) 393-399
34. Wu O., Robertson L., Langhorne P., et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 94 1 (2005) 17-25
35. Herings R.M., Urquhart J., and Leufkens H.G. Venous thromboembolism among new users of different oral contraceptives. Lancet 354 9173 (1999) 127-128 [erratum: Lancet 1999;354(9188):1478]
36. Jick H., Jick S.S., Gurewich V., et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 346 8990 (1995) 1589-1593
37. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 346 (1995) 1575-1582
38. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet 346 8990 (1995) 1593-1596
39. Jick H., Kaye J.A., Vasilakis-Scaramozza C., et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 321 7270 (2000) 1190-1195
40. Bloemenkamp K.W.M., Rosendaal F.R., Buller H.R., et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 159 1 (1999) 65-70
41. Spitzer W.O., Lewis M.A., Heinemann L.A., et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312 7023 (1996) 83-88
42. Vasilakis C., Jick S.S., and Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 59 2 (1999) 79-83
43. Andersen B.S., Olsen J., Nielsen G.L., et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 79 1 (1998) 28-31
44. Bennet L., and Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med 244 1 (1998) 27-32
45. Farmer R.D., Todd J.C., MacRae K.D., et al. Oral contraception was not associated with venous thromboembolic disease in recent study. BMJ 316 7137 (1998) 1090-1091
46. Farmer R.D., Lawrenson R.A., Thompson C.R., et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. [see comment]. Lancet 349 9045 (1997) 83-88
47. Lidegaard O., Edstrom B., and Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 57 5 (1998) 291-301
48. Kemmeren J.M., Algra A., and Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 323 7305 (2001) 131-134
49. Santamaria A., Mateo J., Oliver A., et al. Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. Haematologica 86 9 (2001) 965-971
50. Vandenbroucke J.P., Koster T., Briet E., et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 8935 (1994) 1453-1457
51. Martinelli I., Taioli E., Bucciarelli P., et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 19 3 (1999) 700-703
52. Spannagl M., Heinemann L.A., and Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?. Eur J Contracept Reprod Health Care 5 2 (2000) 105-112
53. Legnani C., Palareti G., Guazzaloca G., et al. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J 23 12 (2002) 984-990
54. Vandenbroucke J.P., Van der Meer F.J.M., Helmerhorst F.M., et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. BMJ 313 7065 (1996) 1127-1130
55. Martinelli I., Sacchi E., Landi G., et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 338 25 (1998) 1793-1797
56. Vandenbrouke J.P., Bloemenkamp K.W., Rosendaal F.R., et al. Incidence of venous thromboembolism in users of combined oral contraceptives. Risk is particularly high with first use of oral contraceptives. BMJ 320 7226 (2000) 57-58
57. Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 160 1 (2000) 49-52
58. Christiansen S.C., Cannegieter S.C., Koster T., et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293 19 (2005) 2352-2361
59. Inman W.H., and Vessey M.P. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. BMJ 2 599 (1968) 193-199
60. Collaborative Group for the Study of Stroke in Young Women. Oral contraception and increased risk of cerebral ischaemia or thrombosis. N Engl J Med 288 (1973) 871-878
61. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 349 9060 (1997) 1202-1209
62. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 348 9026 (1996) 498-505
63. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 348 9026 (1996) 505-510
64. van den Bosch M.A., Kemmeren J.M., Tanis B.C., et al. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost 1 3 (2003) 439-444
65. World Health Organization. Cardiovascular disease and steroid hormone contraception: report of a WHO scientific group. WHO Technical Report Series, 877 (1998), World Health Organization, Geneva, Switzerland
66. Shapiro S., Slone D., Rosenberg L., et al. Oral-contraceptive use in relation to myocardial infarction. Lancet 1 8119 (1979) 743-747
67. Lewis M.A., Heinemann L.A., Spitzer W.O., et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 56 3 (1997) 129-140
68. Farley T.M., Meirik O., and Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. [review]. Hum Reprod Update 5 6 (1999) 721-735
69. Lewis M.A., Spitzer W.O., Heinemann L.A., et al. Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism. BMJ 315 7109 (1997) 679-680
70. Jick H., Jick S., Myers M.W., et al. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 347 9001 (1996) 627-628
71. Dunn N., Thorogood M., Faragher B., et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 318 7198 (1999) 1579-1583
72. Tanis B.C. Oral contraceptives and the risk of myocardial infarction. Eur Heart J 24 5 (2003) 377-380
73. Tanis B.C., van den Bosch M.A., Kemmeren J.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345 25 (2001) 1787-1793
74. Doggen C.J.M., Cats V.M., Bertina R.M., et al. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 97 11 (1998) 1037-1041
75. Rosendaal F.R., Siscovick D.S., Schwartz S.M., et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 90 5 (1997) 1747-1750
76. Rosendaal F.R., Siscovick D.S., Schwartz S.M., et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89 8 (1997) 2817-2821
77. Tanis B.C., Bloemenkamp D.G., van den Bosch M.A., et al. Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 122 3 (2003) 471-478
78. Aznar J., Mira Y., Vaya A., et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost 91 5 (2004) 1031-1034
79. Slooter A.J., Rosendaal F.R., Tanis B.C., et al. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 3 6 (2005) 1213-1217
80. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 290 (1974) 15-19
81. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., et al. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54 (1979) 74-79
82. Petitti D.B., Wingerd J., Pellegrin F., et al. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 242 (1979) 1150-1154
83. Devor M., Barrett-Connor E., Renvall M., et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 92 3 (1992) 275-282
84. Young R.L., Goepfert A.R., and Goldzieher H.W. Estrogen replacement therapy is not conducive of venous thromboembolism. Maturitas 13 3 (1991) 189-192
85. Daly E., Vessey M.P., Painter R., et al. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet 348 9033 (1996) 1027
86. Daly E., Vessey M.P., Hawkins M.M., et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348 9033 (1996) 977-980
87. Grady D., Wenger N.K., Herrington D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132 9 (2000) 689-696
88. Grodstein F., Stampfer M.J., Goldhaber S.Z., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348 9033 (1996) 983-987
89. Jick H., Derby L.E., Myers M.W., et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. [comment]. Lancet 348 9033 (1996) 981-983
90. Perez G.S., Garcia Rodriguez L.A., Castellsague J., et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 314 7083 (1997) 796-800
91. Varas-Lorenzo C., Garcia-Rodriguez L.A., Cattaruzzi C., et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol 147 4 (1998) 387-390
92. Grady D., Hulley S.B., and Furberg C. Venous thromboembolic events associated with hormone replacement therapy. JAMA 278 6 (1997) 477
93. Hoibraaten E., Abdelnoor M., and Sandset P.M. Hormone replacement therapy with estradiol and risk of venous thromboembolism-a population-based case-control study. Thromb Haemost 82 4 (1999) 1218-1221
94. Smith N.L., Heckbert S.R., Lemaitre R.N., et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292 13 (2004) 1581-1587
95. Scarabin P.-Y., Oger E., and Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362 9382 (2003) 9
96. Cushman M., Kuller L.H., Prentice R., et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 292 13 (2004) 1573-1580
97. Hoibraaten E., Qvigstad E., Arnesen H., et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 84 6 (2000) 961-967
98. Rosendaal F.R., Vessey M., Rumley A., et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 116 4 (2002) 851-854
99. Herrington D.M., Vittinghoff E., Howard T.D., et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. [see comment]. Arterioscler Thromb Vasc Biol 22 6 (2002) 1012-1017
100. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
101. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. [see comment]. JAMA 280 7 (1998) 605-613
102. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 1 (2002) 49-57 [erratum: JAMA 2002;288(9):1064]
103. Cherry N., Gilmour K., Hannaford P., et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360 9350 (2002) 2001-2008
104. Lemaitre R.N., Psaty B.M., Heckbert S.R., et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal ischemic stroke in postmenopausal women. Arterioscler Thromb Vasc Biol 22 6 (2002) 1051-1052
105. Psaty B.M., Smith N.L., Lemaitre R.N., et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 285 7 (2001) 906-913
106. Arya R., Shehata H.A., Patel R.K., et al. Internal jugular vein thrombosis after assisted conception therapy. Br J Haematol 115 1 (2001) 153-155
107. Aune B., Hoie K.E., Oian P., et al. Does ovarian stimulation for in-vitro fertilization induce a hypercoagulable state?. Hum Reprod 6 7 (1991) 925-927
108. Baumann P., and Diedrich K. Thromboembolic complications associated with reproductive endocrinologic procedures. Hematol Oncol Clin North Am 14 2 (2000) 431-443
109. Fournet N., Surrey E., and Kerin J. Internal jugular vein thrombosis after ovulation induction with gonadotropins. Fertil Steril 56 2 (1991) 354-356
110. Aurousseau M.H., Samama M.M., Belhassen A., et al. Risk of thromboembolism in relation to an in-vitro fertilization programme: three case reports. Hum Reprod 10 1 (1995) 94-97
111. Moutos D.M., Miller M.M., and Mahadevan M.M. Bilateral internal jugular venous thrombosis complicating severe ovarian hyperstimulation syndrome after prophylactic albumin administration. Fertil Steril 68 1 (1997) 174-176
112. Ulug U., Aksoy E., Erden H., et al. Bilateral internal jugular venous thrombosis following successful assisted conception in the absence of ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 109 2 (2003) 231-233
113. Kligman I., Noyes N., Benadiva C.A., et al. Massive deep vein thrombosis in a patient with antithrombin III deficiency undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 63 3 (1995) 673-676